Advertisement
Singapore markets close in 2 hours 15 minutes
  • Straits Times Index

    3,292.25
    +26.30 (+0.81%)
     
  • Nikkei

    38,229.11
    +155.13 (+0.41%)
     
  • Hang Seng

    18,928.02
    +390.21 (+2.11%)
     
  • FTSE 100

    8,381.35
    +27.30 (+0.33%)
     
  • Bitcoin USD

    62,921.63
    +1,318.12 (+2.14%)
     
  • CMC Crypto 200

    1,351.60
    -6.41 (-0.47%)
     
  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     
  • Dow

    39,387.76
    +331.36 (+0.85%)
     
  • Nasdaq

    16,346.26
    +43.46 (+0.27%)
     
  • Gold

    2,368.20
    +27.90 (+1.19%)
     
  • Crude Oil

    79.91
    +0.65 (+0.82%)
     
  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     
  • FTSE Bursa Malaysia

    1,600.81
    -0.41 (-0.03%)
     
  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     
  • PSE Index

    6,536.51
    -5.95 (-0.09%)
     

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

REDWOOD CITY, Calif. & BOSTON, April 08, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.

Details of the event are as follows:

Panel: "Off-the-Shelf CART – Let’s Talk Lupus and Oncology"
Date: Monday, April 15, 2024
Time: 3:00 p.m. ET

The Adicet Bio team will be available for one-on-one meetings throughout the conference. Please contact your sales representative at Canaccord Genuity to register for a meeting with the company.

ADVERTISEMENT

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408693156/en/

Contacts

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com